Transcatheter Tricuspid Valve Replacement With the Novel System
JACC: Cardiovascular Interventions · 2025-05 · 18 (10) · 1276-1285
DOI: 10.1016/j.jcin.2024.12.030 ↗Kurz gefasst
Klinische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-05. Verfasst von Xiangbin Pan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union…. Hauptthemen laut MEDLINE: Cardiac Catheterization, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Tricuspid Valve. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Transcatheter tricuspid valve replacement (TTVR) is emerging as a promising surgical alternative for high-risk patients with tricuspid regurgitation (TR). Nonetheless, the feasibility of more dedicated devices and the need for additional clinical evidence warrant further exploration. OBJECTIVES: The purpose of this study was to report the 1-year outcomes of the TRAVEL (Transcatheter Right Atrial-Ventricular Valve Replacement With LuX-Valve) study with the LuX-Valve system for patients with severe TR. METHODS: A total of 126 patients with symptomatic severe TR were prospectively enrolled in the single-arm, multicenter TRAVEL study from June 2020 to August 2021. All patients underwent TTVR via the transatrial approach using the LuX-Valve system. The primary endpoint was all-cause mortality and hospitalization for heart failure at 1-year follow-up. Clinical and echocardiographic outcomes were reported. RESULTS: At baseline, all enrolled patients (mean age 65.8 ± 7.5 years, 79.4% women) were at high surgical risk (mean Society of Thoracic Surgeons score 9.2% ± 4.4%), with severe or greater TR and NYHA functional class ≥ III. In 1-year follow-up, all-cause mortality was 10.3%, and 4.0% of patients were hospitalized for heart failure. TR was reduced to mild or less in 95.2% (P < 0.001), with decreases in right atrial systolic volume (-38.3 ± 21.7 mL; P < 0.001) and mid right ventricular end-systolic diameter (-6.4 ± 2.3 mm; P < 0.001). NYHA functional class I or II was achieved in 79.8% (P < 0.001), and 6-minute walking distance increased by 71.3 ± 42.8 m (P < 0.001). CONCLUSIONS: The 1-year outcomes of the TRAVEL study showed a sustained reduction in TR among patients who underwent LuX-Valve TTVR, accompanied by significant right heart reverse remodeling and improved functional status. Favorable procedural success and survival benefits were also demonstrated. (the TRAVEL Trial: Transcatheter Right Atrial-Ventricular Valve Replacement With LuX-Valve; NCT04436653).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
- Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
- Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Cardiovascular Surgery, Anzhen Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Pan, X., Lu, F., Wang, Y., Guo, Y., Chen, M., Meng, X., Zhang, H., Dong, N., Shang, X., Yang, J., Liu, Y., Wang, J., Liu, X., Guo, H., Liu, J., Qiao, F., Ascione, G., Cheung, A., Modine, T., …, & Hu, S. (2025). Transcatheter Tricuspid Valve Replacement With the Novel System. JACC: Cardiovascular Interventions, 18(10), 1276-1285. https://doi.org/10.1016/j.jcin.2024.12.030
Vancouver
Pan X, Lu F, Wang Y, Guo Y, Chen M, Meng X, et al. Transcatheter Tricuspid Valve Replacement With the Novel System. JACC: Cardiovascular Interventions. 2025;18(10):1276-1285. doi:10.1016/j.jcin.2024.12.030
BibTeX
@article{Pan2025,
author = {Pan, Xiangbin and Lu, Fanglin and Wang, Yiwei and Guo, Yingqiang and Chen, Mao and Meng, Xu and Zhang, Haibo and Dong, Nianguo and Shang, Xiaoke and Yang, Jian and Liu, Yang and Wang, Jianan and Liu, Xianbao and Guo, Huiming and Liu, Jian and Qiao, Fan and Ascione, Guido and Cheung, Anson and Modine, Thomas and von Bardeleben, Ralph Stephan and Granada, Juan F and Xu, Zhiyun and Hu, Shengshou},
title = {Transcatheter Tricuspid Valve Replacement With the Novel System},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {10},
pages = {1276--1285},
doi = {10.1016/j.jcin.2024.12.030}
}
EUVIMED